Ontorpacept

Drug Overview

Ontorpacept (also known by its developmental code ASG-15ME) is an investigational antibody-drug conjugate (ADC) designed to target and kill cancer cells that overexpress SLITRK6. SLITRK6 (Slit and NTRK-like protein 6) is a cell-surface protein that is found at high levels in several types of tumors, particularly bladder (urothelial) cancer and certain types of lung cancer, but is minimally present in healthy adult tissues.

In the clinical landscape of March 2026, ontorpacept represents a precision-strike approach to oncology. It consists of a specialized monoclonal antibody chemically linked to a potent cell-killing agent (the “payload”) called monomethyl auristatin E (MMAE). This “Trojan Horse” design allows the drug to circulate through the bloodstream and bind specifically to cancer cells, delivering its toxic payload directly inside the tumor while sparing most healthy cells from the systemic effects of traditional chemotherapy.

• Generic Name: Ontorpacept.
• Code Name: ASG-15ME.
• Drug Class: Antibody-Drug Conjugate (ADC); Antineoplastic Agent.
• Mechanism: Targeting of SLITRK6-expressing cells followed by intracellular release of MMAE to induce cell cycle arrest and apoptosis.
• Route of Administration: Intravenous (IV) infusion.
• FDA Approval Status: Investigational. As of March 2026, ontorpacept is not FDA-approved. It has been evaluated in Phase 1 and Phase 2 trials for metastatic urothelial cancer and is currently being studied for its potential in combination therapies.

What Is It and How Does It Work? (Mechanism of Action)

Ontorpacept works through a sophisticated “lock-and-key” delivery system that destroys cancer cells from the inside out.

1. Targeted Binding (The “Lock”)

The antibody portion of ontorpacept is engineered to recognize and bind to SLITRK6 receptors on the surface of the tumor cell. Because this protein is a “biomarker” for certain aggressive cancers, the drug can ignore cells that do not have this specific “lock.”

2. Internalization and Release (The “Trojan Horse”)

Once the drug binds to the cancer cell, the cell pulls the entire ADC molecule inside through a process called endocytosis.

• Linker Cleavage: Inside the cell’s “stomach” (the lysosome), specialized enzymes cut the chemical linker that holds the drug together.
• Payload Release: This releases the active toxin, MMAE, into the cell’s internal fluid (cytoplasm).

3. Disruption of Cell Division (The “Kill”)

MMAE is an anti-mitotic agent that targets microtubules, which are the “scaffolding” cells need to divide.

• Cell Cycle Arrest: By blocking these microtubules, ontorpacept prevents the cancer cell from splitting into two.
• Apoptosis: Unable to divide and heavily damaged, the cancer cell undergoes apoptosis (programmed cell death).

FDA-Approved Clinical Indications

There are currently no FDA-approved indications for ontorpacept.

Clinical research through 2024–2026 has focused on its potential in several high-unmet-need areas:

• Metastatic Urothelial Cancer: For patients whose bladder cancer has spread and has not responded to standard platinum-based chemotherapy or immunotherapy.
• Lung Cancer: Evaluated in specific subtypes of non-small cell lung cancer (NSCLC) that show high SLITRK6 expression.
• Combination Protocols: Investigated for use alongside checkpoint inhibitors (like pembrolizumab) to see if the ADC can “prime” the tumor for a more aggressive immune attack.

Dosage and Administration Protocols

As an investigational drug, ontorpacept dosing is strictly managed within clinical trial protocols (such as the ASG-15ME-001 study).

Clinical Efficacy and Research Results

As of early 2026, results from Phase 1/2 trials have provided significant biological proof-of-concept:

• Tumor Shrinkage: In patients with metastatic urothelial cancer, ontorpacept has shown an Objective Response Rate (ORR) of approximately 30–40%, which is notable for a population that has already failed multiple lines of therapy.
• Durable Responses: Some patients achieved “durable” responses, meaning the cancer stayed in check for six months or longer.
• Target Confirmation: Clinical biopsies confirmed that patients with the highest levels of SLITRK6 protein on their tumors had the best responses to the drug.

Safety Profile and Side Effects

The side effects of ontorpacept are largely caused by the MMAE payload, which can sometimes “leak” or affect healthy cells that have low levels of the target protein.

1. Peripheral Neuropathy

Because MMAE affects microtubules (which are essential for nerve function), patients may experience:

• Symptoms: Numbness, tingling, or “pins and needles” in the hands and feet.
• Management: This often requires a dose reduction or temporary pause in treatment.

2. Ocular (Eye) Toxicity

A known side effect of several ADCs using this specific payload.

• Symptoms: Blurred vision, dry eyes, or irritation.
• Management: Patients often need regular eye exams and specialized eye drops during treatment.

3. Common Side Effects (>25%):

• Fatigue: General systemic tiredness.
• Nausea and Loss of Appetite: Managed with standard supportive care.
• Anemia and Neutropenia: A drop in red and white blood cells, increasing the risk of infection.

Research Areas

In the fields of Stem Cell and Regenerative Medicine, ontorpacept is being used to study “Targeted Ablation.” Researchers are investigating how SLITRK6 targeting can be used to “clear out” specific populations of malignant stem-like cells in the bladder. In 2026, there is also intense focus on “Next-Generation Linkers.” Scientists are developing more stable chemical bridges for ontorpacept to ensure that the MMAE payload only releases inside the tumor, further reducing the risk of nerve and eye damage.

Patient Management and Practical Recommendations

Pre-treatment Requirements:

• SLITRK6 Biomarker Testing: Most 2026 trials require a fresh or archived tumor biopsy to confirm the cancer expresses the target protein.
• Baseline Eye Exam: To monitor for potential changes in vision.

“Do’s and Don’ts” List:

• DO report any new “tingling” in your fingers or toes immediately; early detection of neuropathy can prevent permanent nerve damage.
• DO use preservative-free artificial tears if you experience dry eyes, as directed by your clinical trial team.
• DON’T miss your scheduled blood work; the drug can lower your white blood cell count without you feeling any symptoms.
• DON’T start any new supplements or “immune boosters” without consulting your oncologist, as they may interfere with the precision mechanism of the drug.

Legal Disclaimer

The information provided is for educational and informational purposes only and does not constitute medical advice. Ontorpacept (ASG-15ME) is an investigational agent and is not approved by the U.S. FDA for commercial use. Access is limited exclusively to registered clinical trials. Always consult with a qualified oncologist regarding your specific diagnosis and eligibility for research participation.